Atyr PHARMA INC (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages

Atyr PHARMA INC (NASDAQ:ATYR) has been assigned a consensus recommendation of “Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $18.60.

Several analysts recently weighed in on ATYR shares. Cantor Fitzgerald initiated coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating for the company. Leerink Partners assumed coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th.

Hedge Funds Weigh In On Atyr PHARMA

Several hedge funds and other institutional investors have recently modified their holdings of ATYR. Group One Trading LLC acquired a new position in Atyr PHARMA during the 4th quarter worth $26,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter valued at about $36,000. Victory Capital Management Inc. acquired a new stake in Atyr PHARMA in the fourth quarter worth about $37,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA in the 4th quarter valued at about $39,000. Finally, XTX Topco Ltd acquired a new position in Atyr PHARMA during the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Trading Up 7.8 %

NASDAQ ATYR opened at $3.60 on Friday. The company’s fifty day simple moving average is $3.29 and its 200-day simple moving average is $3.40. The stock has a market cap of $319.89 million, a P/E ratio of -3.83 and a beta of 0.95. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Equities research analysts predict that Atyr PHARMA will post -0.91 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.